ALPHAMAB-B(09966): The research progress of JSKN003 has been announced during the poster presentation at the 2025 ESMO conference.
Kangning Jeri Pharmaceutical-B (09966) has announced that the research progress of JSKN003 has been completed by October 2025.
ALPHAMAB-B (09966) announced that the research progress of JSKN003 was disclosed during the poster presentation period at the 2025 ESMO Congress, which took place from October 17th to October 21st, 2025.
JSKN003 is a dual-site HER2-targeting ADC, which utilizes glycoengineering technology to link a topoisomerase I inhibitor to the N-glycosylation site of the KN026 antibody (a recombinant humanized anti-HER2 dual-specificity antibody). The coupling reaction during the conjugation process produces conjugates with better serum stability compared to the maleimide-thiol Michael addition reaction. The dual-site HER2 targeting allows JSKN003 to have stronger internalization activity and bystander killing effect, leading to potent anti-tumor activity in HER2-expressing tumors. In September 2024, the company entered into a license agreement with Shanghai Jintan Biotechnology Co., Ltd. to develop, sell, offer for sale, and commercialize JSKN003 for oncology indications in mainland China. Currently, three Phase III clinical trials of JSKN003 for HER2+ BC, HER2-low expression BC, and PROC are ongoing.
Related Articles
CLP Holdings (00002) will distribute a third interim dividend of HK$0.63 per share on December 15th.
CLP Holdings (00002): The electricity sales volume in the first three quarters of the year was 27.456 billion kilowatt-hours, a year-on-year decrease of 1.8%.
CSC DEVELOPMENT (00830) reported a revenue of approximately 4.709 billion Hong Kong dollars in the first three quarters, a decrease of 28.01% year-on-year.
CLP Holdings (00002) will distribute a third interim dividend of HK$0.63 per share on December 15th.
CLP Holdings (00002): The electricity sales volume in the first three quarters of the year was 27.456 billion kilowatt-hours, a year-on-year decrease of 1.8%.
CSC DEVELOPMENT (00830) reported a revenue of approximately 4.709 billion Hong Kong dollars in the first three quarters, a decrease of 28.01% year-on-year.
RECOMMEND
